InspireMD Q4 Revenue $3.1M Beats Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Should l Buy NSPR?
Reports Q4 revenue $3.1M, consensus $2.63M. "We continue to see robust early momentum in our U.S. business with CGuard Prime and growing demand internationally for CGuard as we build a platform designed to position us to be a global leader in the treatment of carotid artery disease and the prevention of stroke," said Marvin Slosman, CEO of InspireMD. "In addition, we are committed to advancing CGuard Prime for use in TCAR procedures. Once approved, this will potentially double our addressable U.S. market opportunity. We expect more catalysts in 2026 that may accelerate the adoption of our next-generation stent platform and the growth of our business."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NSPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NSPR
Wall Street analysts forecast NSPR stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.590
Low
5.00
Averages
5.00
High
5.00
Current: 1.590
Low
5.00
Averages
5.00
High
5.00
About NSPR
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
InspireMD Reports 62% Revenue Growth in Q4 2025 Driven by Seaguard Prime Launch
- Significant Revenue Growth: InspireMD Inc (NASDAQ:NSPR) reported a 62% increase in total revenue for Q4 2025, driven by the launch of Seaguard Prime in the US and enhanced international market penetration, indicating strong momentum in market expansion.
- Gross Margin Improvement: The gross margin for US sales reached approximately 70%, attributed to strong pricing and value, demonstrating success in the company's pricing strategy and laying a foundation for future profitability.
- Advancement in Clinical Pipeline: The company is advancing multiple clinical programs, including the SeaGuardians 2 trial, which could expand market opportunities and further enhance its competitiveness in the medical device sector.
- Financial Stability: InspireMD Inc holds $54.2 million in cash and equivalents, and despite reporting a net loss of $11.8 million, the strong cash position provides financial support for future growth initiatives.
See More
InspireMD Reports Q4 2025 Earnings with Strong Growth and Strategic Outlook
- Significant Revenue Growth: InspireMD reported total revenue of $3.1 million for Q4 2025, a 62% increase year-over-year, with U.S. revenue at $866,000 and international revenue at $2.3 million, demonstrating strong market performance of the CGuard Prime product.
- Accelerated Clinical Progress: The C-GUARDIANS II trial has been completed, with FDA approval anticipated in Q3 2026, while the upcoming CGUARDIANS III trial will begin enrollment in Q2 2026, marking ongoing advancements in the company's clinical pipeline.
- Operational Expansion and Team Building: The company has established a U.S. production base and built a commercial team of over 30 people, primarily in the field, aimed at addressing the growing U.S. market demand and enhancing competitive positioning.
- Optimistic Future Outlook: InspireMD expects 2026 revenue to range between $13 million and $15 million, reflecting approximately 45% to 65% growth, primarily driven by FDA label expansion for CGuard Prime and the introduction of new product offerings.
See More
InspireMD Q4 Earnings Exceed Expectations
- Earnings Highlights: InspireMD reported a Q4 GAAP EPS of -$0.14, yet achieved revenues of $3.15 million, a 61.5% year-over-year increase, surpassing expectations by $0.52 million, indicating strong market performance.
- U.S. Market Growth: Revenue from the U.S. reached $0.9 million during the second quarter post-launch of CGuard Prime, reflecting a sequential growth of 74%, demonstrating significant market acceptance of the new product and improving overall company performance.
- International Market Expansion: International revenue totaled $2.3 million, marking a 17% increase over Q4 2024, which highlights the enhanced penetration of CGuard in international markets, thereby strengthening the company's competitive position globally.
- Investor Interest: InspireMD's financial performance has garnered investor attention, particularly in the context of strong performances from companies like Micron and Babcock & Wilcox, reflecting market confidence in its future growth prospects.
See More
InspireMD to Announce Q4 Earnings on March 18
- Earnings Announcement Date: InspireMD is set to release its Q4 earnings report on March 18 before market open, with market participants keenly awaiting the results to gauge stock price movements.
- Earnings Expectations: The consensus EPS estimate stands at -$0.19, flat year-over-year, indicating ongoing challenges in the company's profitability recovery efforts.
- Revenue Growth Forecast: The revenue estimate is projected at $2.63 million, reflecting a 34.9% year-over-year increase, signaling positive momentum in market demand and product sales growth.
- Historical Performance Review: Over the past year, InspireMD has exceeded EPS estimates 50% of the time and has beaten revenue estimates 100% of the time, demonstrating stability in its revenue growth trajectory.
See More
InspireMD to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: InspireMD will announce its fourth quarter and full year 2025 financial results on March 18, 2026, reflecting the company's ongoing efforts and achievements in stroke prevention.
- Conference Call Details: Following the earnings release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to share financial results and recent highlights, enhancing transparency and communication with investors.
- Technological Edge: InspireMD aims to establish its proprietary MicroNet™ mesh technology as the industry standard for carotid stenting, providing outstanding acute results and durable, stroke-free long-term outcomes, thereby strengthening its market position.
- Investor Information Access: The company regularly posts important information for investors on its website, encouraging them to visit for the latest updates and financial information, thereby improving investor relations management.
See More
InspireMD Publishes Positive CREST-2 Data Confirming Efficacy of Carotid Stenting
- CREST-2 Study Results: InspireMD presented CREST-2 data at the SVIN Annual Meeting on November 21, 2025, showing that carotid artery stenting (CAS) significantly outperformed intensive medical management for patients with asymptomatic carotid stenosis. This finding provides crucial clinical evidence that could reshape treatment protocols for carotid disease.
- Clinical Trial Scale: The CREST-2 trial, independently conducted and NIH-sponsored, involved 155 centers globally with 1,245 patients randomized to the stenting group. Results indicated a significantly reduced risk of perioperative stroke or death over four years, underscoring the efficacy of stenting.
- Innovative Technology Advantage: InspireMD's CGuard®Prime stent demonstrated a record-low 1.93% major adverse event rate in the C-GUARDIANS trial, particularly among high-risk patients. This low event rate, combined with the positive CREST-2 results, reinforces the company's leadership in the carotid stenting market.
- Market Outlook: CEO Marvin Slosman stated that CREST-2 validates the superiority of combining stenting with medical management, indicating a shift towards an endovascular-first approach in vascular disease treatment. With growing recognition of effective treatments for asymptomatic carotid disease, InspireMD is poised for increased market share.
See More
InspireMD Reports 62% Revenue Growth in Q4 2025 Driven by Seaguard Prime Launch
- Significant Revenue Growth: InspireMD Inc (NASDAQ:NSPR) reported a 62% increase in total revenue for Q4 2025, driven by the launch of Seaguard Prime in the US and enhanced international market penetration, indicating strong momentum in market expansion.
- Gross Margin Improvement: The gross margin for US sales reached approximately 70%, attributed to strong pricing and value, demonstrating success in the company's pricing strategy and laying a foundation for future profitability.
- Advancement in Clinical Pipeline: The company is advancing multiple clinical programs, including the SeaGuardians 2 trial, which could expand market opportunities and further enhance its competitiveness in the medical device sector.
- Financial Stability: InspireMD Inc holds $54.2 million in cash and equivalents, and despite reporting a net loss of $11.8 million, the strong cash position provides financial support for future growth initiatives.
See More
InspireMD Reports Q4 2025 Earnings with Strong Growth and Strategic Outlook
- Significant Revenue Growth: InspireMD reported total revenue of $3.1 million for Q4 2025, a 62% increase year-over-year, with U.S. revenue at $866,000 and international revenue at $2.3 million, demonstrating strong market performance of the CGuard Prime product.
- Accelerated Clinical Progress: The C-GUARDIANS II trial has been completed, with FDA approval anticipated in Q3 2026, while the upcoming CGUARDIANS III trial will begin enrollment in Q2 2026, marking ongoing advancements in the company's clinical pipeline.
- Operational Expansion and Team Building: The company has established a U.S. production base and built a commercial team of over 30 people, primarily in the field, aimed at addressing the growing U.S. market demand and enhancing competitive positioning.
- Optimistic Future Outlook: InspireMD expects 2026 revenue to range between $13 million and $15 million, reflecting approximately 45% to 65% growth, primarily driven by FDA label expansion for CGuard Prime and the introduction of new product offerings.
See More
InspireMD Q4 Earnings Exceed Expectations
- Earnings Highlights: InspireMD reported a Q4 GAAP EPS of -$0.14, yet achieved revenues of $3.15 million, a 61.5% year-over-year increase, surpassing expectations by $0.52 million, indicating strong market performance.
- U.S. Market Growth: Revenue from the U.S. reached $0.9 million during the second quarter post-launch of CGuard Prime, reflecting a sequential growth of 74%, demonstrating significant market acceptance of the new product and improving overall company performance.
- International Market Expansion: International revenue totaled $2.3 million, marking a 17% increase over Q4 2024, which highlights the enhanced penetration of CGuard in international markets, thereby strengthening the company's competitive position globally.
- Investor Interest: InspireMD's financial performance has garnered investor attention, particularly in the context of strong performances from companies like Micron and Babcock & Wilcox, reflecting market confidence in its future growth prospects.
See More
InspireMD to Announce Q4 Earnings on March 18
- Earnings Announcement Date: InspireMD is set to release its Q4 earnings report on March 18 before market open, with market participants keenly awaiting the results to gauge stock price movements.
- Earnings Expectations: The consensus EPS estimate stands at -$0.19, flat year-over-year, indicating ongoing challenges in the company's profitability recovery efforts.
- Revenue Growth Forecast: The revenue estimate is projected at $2.63 million, reflecting a 34.9% year-over-year increase, signaling positive momentum in market demand and product sales growth.
- Historical Performance Review: Over the past year, InspireMD has exceeded EPS estimates 50% of the time and has beaten revenue estimates 100% of the time, demonstrating stability in its revenue growth trajectory.
See More
InspireMD to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: InspireMD will announce its fourth quarter and full year 2025 financial results on March 18, 2026, reflecting the company's ongoing efforts and achievements in stroke prevention.
- Conference Call Details: Following the earnings release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to share financial results and recent highlights, enhancing transparency and communication with investors.
- Technological Edge: InspireMD aims to establish its proprietary MicroNet™ mesh technology as the industry standard for carotid stenting, providing outstanding acute results and durable, stroke-free long-term outcomes, thereby strengthening its market position.
- Investor Information Access: The company regularly posts important information for investors on its website, encouraging them to visit for the latest updates and financial information, thereby improving investor relations management.
See More
InspireMD Publishes Positive CREST-2 Data Confirming Efficacy of Carotid Stenting
- CREST-2 Study Results: InspireMD presented CREST-2 data at the SVIN Annual Meeting on November 21, 2025, showing that carotid artery stenting (CAS) significantly outperformed intensive medical management for patients with asymptomatic carotid stenosis. This finding provides crucial clinical evidence that could reshape treatment protocols for carotid disease.
- Clinical Trial Scale: The CREST-2 trial, independently conducted and NIH-sponsored, involved 155 centers globally with 1,245 patients randomized to the stenting group. Results indicated a significantly reduced risk of perioperative stroke or death over four years, underscoring the efficacy of stenting.
- Innovative Technology Advantage: InspireMD's CGuard®Prime stent demonstrated a record-low 1.93% major adverse event rate in the C-GUARDIANS trial, particularly among high-risk patients. This low event rate, combined with the positive CREST-2 results, reinforces the company's leadership in the carotid stenting market.
- Market Outlook: CEO Marvin Slosman stated that CREST-2 validates the superiority of combining stenting with medical management, indicating a shift towards an endovascular-first approach in vascular disease treatment. With growing recognition of effective treatments for asymptomatic carotid disease, InspireMD is poised for increased market share.
See More
